Viral Genetics Inc. Invited to Present New Model, Initial Findings of Lyme Disease Study at Prestigious ILADS Conference

AZUSA, Calif.--(BUSINESS WIRE)--Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today announced it has been invited to present and discuss its new Lyme Disease study model and initial findings at the 2008 International Lyme & Associated Diseases Society (ILADS) Scientific Session. The study could also potentially offer answers to other immune based diseases including HIV/AIDS. In addition, the study team has begun to further explore its new model in Lyme Disease, which researchers hope will reconcile the long-standing and controversial debate in the medical community over treatment methods for Lyme Disease.